Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 9:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 1,800 matching trials from the live ClinicalTrials.gov search.
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
pemetrexed disodium
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Renal Cell Carcinoma (RCC), Alveolar Soft Part Sarcoma (ASPS), Clear Cell Sarcoma (CCS)
Interventions
ARQ 197
Drug
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
13 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
7
States / cities
San Francisco, California • Santa Monica, California • Miami, Florida + 4 more
Conditions
Kidney Cancer
Interventions
estramustine phosphate sodium, prednisone, vinorelbine tartrate
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
Up to 120 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Albuquerque, New Mexico
Conditions
Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Breast Cancer, Cancer of Breast, Cancer of the Breast, Gastroesophageal Cancer, Pancreatic Cancer, Cancer of the Pancreas, Colorectal Cancer, Colorectal Carcinoma, Renal Cancer, Kidney Cancer, Cancer of the Kidney, Cancer of Kidney, Ovarian Cancer, Ovary Cancer, Cancer of the Ovary, Cancer of Ovary
Interventions
MEDI4736
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Solid Tumor, Microsatellite Stable Colorectal Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Cervical Cancer, Melanoma (Skin), Cutaneous Squamous Cell Carcinoma, Mesothelioma, Renal Cell Carcinoma, Oropharynx Cancer
Interventions
TBio-6517, Pembrolizumab
Biological
Lead sponsor
Turnstone Biologics, Corp.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Phoenix, Arizona • Jacksonville, Florida • Miami, Florida + 5 more
Conditions
Renal Cell Carcinoma, Renal Cell Carcinoma Stage IV
Interventions
Nivolumab, Ipilimumab, bland embolization
Drug · Device
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Advanced Melanoma, Renal Cell Carcinoma
Interventions
Nivolumab, Ipilimumab, APX005M
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
New Haven, Connecticut
Conditions
Select Advanced Malignancies, Kidney Cancer, Clear Cell Renal Cell Carcinoma
Interventions
MEDI0680, Durvalumab, Nivolumab
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
13
States / cities
Los Angeles, California • Tampa, Florida • Overland Park, Kansas + 10 more
Conditions
Locally Advanced Papillary Renal Cell Carcinoma, Metastatic Papillary Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma, Unresectable Renal Cell Carcinoma
Interventions
Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Crizotinib, Savolitinib, Sunitinib Malate
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
586
States / cities
Anchorage, Alaska • Kingman, Arizona • Fort Smith, Arkansas + 361 more
Conditions
Renal Cell Carcinoma, Pharmacokinetics of AGS-16M8F
Interventions
AGS-16M8F
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Seattle, Washington
Conditions
Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)
Interventions
Regorafenib
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
3
States / cities
Birmingham, Alabama • Detroit, Michigan • Cleveland, Ohio
Conditions
Bladder Cancer, Bladder Stone, Bladder Outlet Obstruction, Renal Stone, Renal Disease
Interventions
Cystoscopy with RedPine flexible disposable cystoscope, Cystoscopy with standard of care flexible reusable scope
Device
Lead sponsor
Guangzhou Red Pine Medical Instrument Co., Ltd.
Industry
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Hersey, Pennsylvania • Dallas, Texas • Seattle, Washington
Conditions
Bladder Cancer, Glioma, Glioblastoma (GBM), Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer (GC), Pharynx Cancer, Oral Cavity Cancer, Kidney Cancer, Liver Cancer, Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Prostate Cancer
Interventions
[64Cu]CM500, [68Ga]CM500, PET/MR, PET/CT, Blood Collection
Drug · Device · Procedure
Lead sponsor
Lumina Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
3
States / cities
Boston, Massachusetts • Grand Rapids, Michigan • New York, New York
Conditions
Metastatic Cancer
Interventions
ASA404, DMXAA or DXAA
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
4
States / cities
Indianapolis, Indiana • Rockville, Maryland • Detroit, Michigan + 1 more
Conditions
Renal Cell Carcinoma
Interventions
Non-renorrhaphy, Renorrhaphy
Procedure
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer
Interventions
Bevacizumab, Laboratory Biomarker Analysis, Pazopanib Hydrochloride, Pharmacological Study
Biological · Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
5
States / cities
Westwood, Kansas • Detroit, Michigan • Buffalo, New York + 2 more
Conditions
Prostate Cancer Stage I, Kidney Cancer Stage I, Bladder Cancer Stage II, Prostate Cancer Stage II
Interventions
Patient-centered communication of life expectancy
Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma
Interventions
Anti-Endoglin Chimeric Monoclonal Antibody TRC105, Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
28
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 24 more
Conditions
Relapsed Pediatric Solid Tumors, Refractory Pediatric Solid Tumors, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma, Neuroblastoma, Wilms Tumor, Hepatic Tumor, Germ Cell Tumor, Desmoid Tumor
Interventions
Magnetic Resonance High Intensity Focused Ultrasound
Device
Lead sponsor
AeRang Kim
Other
Eligibility
Up to 30 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Cincinnati, Ohio
Conditions
Esophageal Neoplasms, Lung Neoplasms, Mesothelioma, Thymus Neoplasms, Neoplasms, Germ Cell and Embryonal
Interventions
Mithramycin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Urothelial Carcinoma
Interventions
Nephroureterectomy, Lymph Node Dissection
Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
19 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
4
States / cities
Gainesville, Florida • Springfield, Illinois • Cleveland, Ohio
Conditions
Clear Cell Renal Cell Carcinoma, Kidney Cancer, Advanced Renal Cell Carcinoma
Interventions
177Lu-labeled-girentuximab, Nivolumab, 89Zr-girentuximab PET/CT, 177Lu whole body (WB) planar and SPECT/CT scans
Drug · Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Lifileucel (TIL) Therapy After PD-1 Blockade Failure in Kidney Cancer

NCT07925333
Conditions
Kidney Cancers, Renal Cell Carcinoma (Kidney Cancer)
Interventions
Cyclophosphamide, Fludarabine, Aldesleukin (IL-2), Tumor Resection
Drug · Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2030
U.S. locations
3
States / cities
Boston, Massachusetts
Conditions
Clear Cell Renal Cell Carcinoma
Interventions
Nivolumab and rHuPH20, Nivolumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Chicago, Illinois • Buffalo, New York • West Reading, Pennsylvania